The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland - An analysis of the RENAAL study

Swiss Medical Weekly

Volumn 134, Issue 31-32, 2004, Pages 440-447

  Szucs, Thomas D ^a,c   Sandoz, Menga S ^a   Keusch, Gérald W ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Stadtspital Waid   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cost effectiveness analysis; Diabetes; Losartan; Nephropathy; Switzerland

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SWITZERLAND; TELEPHONE; TREATMENT OUTCOME;

EID: 4544364601     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ritz E, Stefansky A. Diabetic nephropathv in type II diabetes. Am J Kidney Dis 1996;27:67-94.
2. Ritz F, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
3. Ismail N, Becker B, Strzelezyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999;55:1-28.
4. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
5. Mackenbach JP, Kunst AE, Lautenbach H, Oei YB, Bijlsma F. Competing causes of death: a death certificate study. J Clin Epidemiol 1997;50:1069-77.
6. Thomas RJ, Palumbo PJ, Melton LJ 3rd, Roger VL, Ransom J, O'Brien PC, et al. Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med 2003;163:445-51.
7. Ritz E. Nephropathy in type 2 diabetes. J Intern Med 1999;245:111-26.
8. Fliser D, Haller H. nephropathy bei Diabetes mellitus type 2. Der Internist 2000;41:1363-73.
9. Bruno G, Biggeri A, Merletti F, Bargero G, Ferrero S, Pagano C, et al. Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study. Diabetes Care 2003;26:2353-8.
10. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:1122-8.
11. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs ot complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476-81.
12. Liebl A, Carides GW, Gerth WC, Krobot KJ. losartan reduces the medical burden and costs associated with ESRD. Implications from the RENAAL Study for Germany. Poster des Kongresses der European Association for the Study of Diabetes, 38. Jahrestreffen, 1.-5. September 2002, Budapest, Ungarn.
13. USRDS Annual Report 2000. www.usrds.org. Zugegriffen am 27. November 2002.
14. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-8.
15. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
16. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
17. Viberti G, Wheeldom NM, for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
18. Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT - the emergence of new treatment options. J Clin Hypertens 2002;4:52-7.
19. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003;21:1-15.
20. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Brenner BM for the RENAAL Investigators. losartan reduces the costs associated with ESRD: economic evaluation. Poster ASN/ISN Weltkongresses der Nephrologie, 13.-17. Oktober 2001, San Francisco, USA.
21. Sandoz MS, Ess SM, Keusch GW, Schwenkglenks M, Szucs TD. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. Swiss Med Wkly 2004;134:448-58.
22. Schweizerischer Dialysevertrag zwischen H+ Die Spitäler der Schweiz, Aarau und dem SVK Schweizerischer Verband für Gemeinschattsautgaben der Krankenversicherer, Solothurn. Anhang: Tarif, Position 11*, per 1. Juli 1998.
23. Schweizerischer Dialysevertrag zwischen H+ Die Spitäler der Schweiz, Aarau und dein SVK Schweizerischer Verband für Gemeinschaftsaufgaben der Krankenversicherer, Solothurn. Anhang: Tarif, Position 22*, per 1. Juli 1998.
24. Schweizerischer Verband für Gemeinschaftsaufgaben der Krankenversicherer SVK. Vertrag über Transplantation solider Organe. Anhang 2 Abschnitt 1, per 1. November 2001.
25. Schweizerischer Verband für Gemeinschaftsaufgaben der Krankenversicherer SVK. Vertrag über HLA-Typisierung bei Nierentransplantationen bzw. Nieren-Pankreastransplantationen (bzw. Nieren und Langerhans'sche Inseln), per 1. November 1999.
26. Schweizerischer Verband für Gemeinschaftsaufgaben der Krankenversicherer SVK. Vertrag über Angabenbestimmung bezüglich Immunologie bei Nierentransplantationen bzw. Nieren-Pankreastransplantationen (bzw. Nieren und Langerhans'sche Inseln), per 1. Juli 1999.
27. Spezialitätenliste (Stand 1.07.2001). www.bsv.admin.ch/sl/liste/d/ index.htm. Zugegriffen im Juli 2002.
28. Leistungsorientierte Abgeltung(LOA) für Apothekerinnen und Apotheker (mit Einführung ab 1. Juli 2001).
29. Krankenversicherungsgesetz KVG: Artikel 64, Absatz. 2 und Verordnung über die Krankenversicherung (KVV) vom 27. Juni 1995: Artikel 103, Absatz. 1 und 2.
30. Gerth WC, Viberti GC, Remuzzi G, Hannedouche T, Martinez-Castelao A, Shahinfar S, et al. losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Poster des Kongresses der European Association for the Study of Diabetes, 38. Jahrestreffen, 1.-5. September 2002, Budapest, Ungarn.
31. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, et al. losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation. Diabetes Care 2003;26:683-7.
32. Nebel M. Behandlungskosten der Nierenersatztherapie in Deutschland 1999. Nieren- und Hochdruckkrankheiten 2002;31:85-92.
33. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ. An economic evaluation irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephropathy Dial Transplant 2003;18:2059-66.
34. Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, et al. Collaborative Study Group. The cost-effectiveness of irBesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003;25:2102-19.
35. Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003;29:29-35.
36. Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care 2003;26:683-7.
37. Deferrari G, Ravera M, Deferrari L, Vetroretti S, Ratto E, Parodi D. Renal und cardiovascular protection in type 2 diabetes mellitus: Angiotensin II receptor blockers. J Am Soc Nephrol 2002;13(Suppl 3):224-9).
38. Gozzoli V, Palmer AJ, Brandt A, Spinas CA, Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Swiss Med Wkly 2001;131:303-10.